Jove
Visualize
Contact Us

Related Experiment Videos

Anti-restenosis Trials.

de Feyter PJ1, Vos, Rensing

  • 1Thoraxcenter, University Hospital Rotterdam, Bd 410, PO Box 2040, Rotterdam 3000 CA, The Netherlands. defeyter@card.azr.nl

Current Interventional Cardiology Reports
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Photon correlation spectroscopy: X rays versus visible light

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2000
Same author

Toxicity of TCDD in European flounder (Platichthys flesus) with emphasis on histopathology and cytochrome P450 1A induction in several organ systems.

Aquatic toxicology (Amsterdam, Netherlands)·2000
Same author

Ultrasound Appearances of Coronary Stents as Obtained by Three-Dimensional Intracoronary Ultrasound Imaging In Vitro.

The Journal of invasive cardiology·2000
Same author

Preparation of photonic crystals made of air spheres in titania

Science (New York, N.Y.)·1998
Same author

Electronic-structure investigation of oxidized aluminum films with electron-momentum spectroscopy.

Physical review. B, Condensed matter·1996
Same author

Monte Carlo simulations of (e,2e) experiments on solids.

Physical review. B, Condensed matter·1996
Same journal

Rashkind and Clamshell Device Closure of Ventricular Septal Defect.

Current interventional cardiology reports·2001
Same journal

The Role of the 'Sideris' Devices in the Occlusion of Ventricular Septal Defects.

Current interventional cardiology reports·2001
Same journal

A Comparison of Tirofiban and Abciximab in Patients Undergoing Coronary Stent Implantation: Rationale, Design, and Results of the TARGET Trial.

Current interventional cardiology reports·2001
Same journal

Diabetes and Coronary Intervention: Special Considerations for Antithrombotic Therapy.

Current interventional cardiology reports·2001
Same journal

'Facilitated' PCI for Acute MI: PCI with Lysis and Platelet Inhibition.

Current interventional cardiology reports·2001
Same journal

Restenosis and Reocclusion after Recanalization of an Occluded Coronary Artery: Is There a Light at the End of This Tunnel?

Current interventional cardiology reports·2001
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Restenosis after angioplasty remains a challenge, affecting 30-60% of patients. While stents help in some cases, in-stent restenosis and restenosis in long lesions or small vessels are still significant problems.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Medical Device Technology

Background:

  • Restenosis, the re-narrowing of arteries after angioplasty, affects 30-60% of patients, limiting long-term success.
  • Pharmacologic agents have shown limited efficacy, with few drugs approved and ongoing trials for others.
  • Stent implantation has improved outcomes for specific lesion types but has not resolved all restenosis issues.

Purpose of the Study:

  • To review the current challenges and advancements in managing restenosis following percutaneous coronary angioplasty.
  • To evaluate the effectiveness of different treatment modalities, including pharmacologic agents and stenting.
  • To identify unresolved issues in restenosis treatment, particularly in-stent restenosis and specific lesion characteristics.

Main Methods:

Related Experiment Videos

  • Review of clinical trials and existing literature on restenosis after percutaneous coronary angioplasty.
  • Analysis of the impact of various pharmacologic agents on restenosis rates.
  • Evaluation of the role and limitations of coronary stent implantation in preventing restenosis.
  • Assessment of emerging therapies like brachytherapy for specific restenosis scenarios.

Main Results:

  • Pharmacologic interventions have largely failed to effectively prevent restenosis, with limited exceptions and ongoing investigations.
  • Coronary stenting has significantly reduced restenosis in specific patient groups and lesion types.
  • In-stent restenosis remains a major challenge, often recurring after repeat interventions.
  • Restenosis in long lesions and small vessels continues to be an unresolved clinical problem.

Conclusions:

  • Despite advancements, restenosis after percutaneous coronary angioplasty persists as a significant clinical problem.
  • Coronary stenting offers benefits but does not eliminate the risk, especially for in-stent restenosis.
  • Further research and novel therapeutic strategies are needed to address persistent restenosis challenges, particularly in complex lesion subsets.